Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240998 | 0.90 | BAZ2B (0.70) | BAZ2BMAPK14 | |
| SCHEMBL1091777 | 0.85 | BAZ2B (0.82) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL7005456 | 0.84 | MAPK14 (0.74) | BAZ2BMAPK14NPC1RAB9A | |
| SCHEMBL21505098 | 0.82 | BAZ2B (0.60) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL1091597 | 0.82 | BAZ2B (0.60) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL26332851 | 0.81 | BAZ2B (0.55) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL27690165 | 0.81 | BAZ2B (0.55) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL17983689 | 0.81 | BAZ2B (0.67) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL10751140 | 0.81 | BAZ2B (0.55) | BAZ2BMAPK14NPC1RAB9ACASP1 | |
| SCHEMBL2000310 | 0.81 | BAZ2B (0.55) | BAZ2BNPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3447045-B9 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-07-21 | — | — | EP | disclosed |
| EP-3447045-B1 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-20190127320-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127320-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | BAZ2B 2808/4885MAPK14 2251/4885NPC1 3272/4885 |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | BAZ2B 352/4885MAPK14 583/4885NPC1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.